Analyst See $38 Price Target for Tesla Motors, as Amylin, Nanometrics, HCA and Kenexa at Outperform
Tesla Motors, Inc.(NASDAQ:TSLA): Barclays believes Tesla’s new Model X SUV launch will highlight its innovation capabilities and differentiation. The firm rates shares an Overweight with a $38 price target.
Amylin Pharmaceuticals, Inc.(NASDAQ:AMLN): Baird raised its price target on Amylin following Q4 results. The firm cited the potential for a successful US partnership transaction and the launch of Bydureon on February 17. Shares are Outperform rated.
Nanometrics Incorporated(NASDAQ:NANO): RBC Capital raised its Q1 revenue estimate for Nanometrics to reflect strong increases in spending by the company’s leading customers. The firm maintains an Outperform rating on the stock.
HCA Holdings Inc(NYSE:HCA): Baird raised its price target on HCA Holdings following Q4 results. The firm cited stabilization in commercial volumes, expense management, solid balance sheet, and the special $2.00 per share dividend announcement. Shares are Outperform rated.
Kenexa Corp.(NASDAQ:KNXA): Cowen said Kenexa delivered better than expected Q4 results. The firm maintains its Outperform rating citing a strong pipeline, solid organic growth, and conservative guidance.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com